Compare AbCellera Biologics Inc (ABCL) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs ProShares Ultra QQQ ETF — how do they compare? AbCellera Biologics Inc trades at $10.12 (market cap $2.99B), while ProShares Ultra QQQ ETF trades at $92.71. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, ProShares Ultra QQQ ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | QLD | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $9.76 | $100.53 |
52-Week Low | $2.78 | $57.16 |
Enterprise Value | $2.58B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
QLD, the ProShares Ultra QQQ ETF, trades at $92.56, up 1.01% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF, offering 2x daily leverage on the Nasdaq-100, has delivered over 10,000% total return since inception, though it carries amplified risk. Recent institutional buying includes 180 Wealth Advisors increasing its position by 29.4% in Q2 2026, signaling confidence in tech exposure.
The outlook for QLD hinges on tech sector performance, with AI optimism and easing geopolitical tensions as tailwinds. However, leveraged ETF structure risks decay in volatile markets, and a 63.80% historical drawdown underscores volatility. Investors seeking aggressive tech growth may find opportunity, but must tolerate significant swings; diversification and risk management are critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
